Coronavirus disease-2019 in the immunocompromised host
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a respiratory virus that
originated in Wuhan, China in 2019. Since that time, SARS-CoV-2 has been responsible for …
originated in Wuhan, China in 2019. Since that time, SARS-CoV-2 has been responsible for …
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
Limited data are available on breakthrough COVID-19 in patients with hematologic
malignancy (HM) after anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
malignancy (HM) after anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19
Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2), has created a global pandemic infecting over 230 million …
Coronavirus 2 (SARS-CoV-2), has created a global pandemic infecting over 230 million …
Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer
Patients with cancer are at greater risk of severe COVID-19 and have been prioritised for
COVID-19 vaccination globally. We previously showed that following two doses of COVID …
COVID-19 vaccination globally. We previously showed that following two doses of COVID …
Outcomes of the SARS-CoV-2 omicron (B. 1.1. 529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the …
Summary Background The omicron (B. 1.1. 529) variant of SARS-CoV-2 is highly
transmissible and escapes vaccine-induced immunity. We aimed to describe outcomes due …
transmissible and escapes vaccine-induced immunity. We aimed to describe outcomes due …
Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study …
Summary Background Breakthrough SARS-CoV-2 infections following vaccination against
COVID-19 are of international concern. Patients with cancer have been observed to have …
COVID-19 are of international concern. Patients with cancer have been observed to have …
Seroconversion and outcomes after initial and booster COVID‐19 vaccination in adults with hematologic malignancies
Background Patients with hematologic malignancies have impaired humoral immunity
secondary to their malignancy and its treatment, placing them at risk of severe coronavirus …
secondary to their malignancy and its treatment, placing them at risk of severe coronavirus …
Age-associated B cells predict impaired humoral immunity after COVID-19 vaccination in patients receiving immune checkpoint blockade
Age-associated B cells (ABC) accumulate with age and in individuals with different
immunological disorders, including cancer patients treated with immune checkpoint …
immunological disorders, including cancer patients treated with immune checkpoint …
[HTML][HTML] Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities
Background The successful development of multiple COVID-19 vaccines has led to a global
vaccination effort to reduce severe COVID-19 infection and mortality. However, the …
vaccination effort to reduce severe COVID-19 infection and mortality. However, the …
[HTML][HTML] Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer
Abstract Background Although SARS-CoV-2 vaccines immunogenicity in patients with
cancer has been investigated, whether they can significantly improve the severity of COVID …
cancer has been investigated, whether they can significantly improve the severity of COVID …